ArticleEuropean journal of nuclear medicine and molecular imaging2021
Can
Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The predictive value of PSMA PET/CT in determining pathological upgrading of prostate cancer: A pooling up analysis.Frontiers in oncology · 2025Pooled it
- Transrectal Ultrasound-Guided Prostate Biopsy with and without PSMA-PET-Targeted Prostate Biopsy for Prostate Cancer Diagnosis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Development and validation of prostate-specific membrane antigen-adjusted Prostate Imaging Reporting and Data System: A new approach to enhancing the accuracy of diagnosing treatment-naïve primary prostate cancer.Asian journal of urology · 2026Article
- The predictive value of multiparametric MRI combined with [European journal of nuclear medicine and molecular imaging · 2025Article
- A PSMA PET/CT-based risk model for prediction of concordance between targeted biopsy and combined biopsy in detecting prostate cancer.World journal of urology · 2024Article
- Analytical performance validation of aPROMISE platform for prostate tumor burden, index and dominant tumor assessment with 18F-DCFPyL PET/CT. A pilot study.Scientific reports · 2024Article
- Prostate-specific membrane antigen-targeted surgery in prostate cancer: Accurate identification, real-time diagnosis, and precise resection.Theranostics · 2024Review
- A Systematic Review of the Variability in Performing and Reporting Intraprostatic Prostate-specific Membrane Antigen Positron Emission Tomography in Primary Staging Studies.European urology open science · 2023Article
- Deep learning based on 68Ga-PSMA-11 PET/CT for predicting pathological upgrading in patients with prostate cancer.Frontiers in oncology · 2023Article
- The prognostic value ofFrontiers in oncology · 2023Article
- Establishment and prospective validation of an SUVTheranostics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeProstate-specific membrane antigen (PSMA) positron emission tomography (PSMA-PET) is an ideal tool for staging and restaging of prostate cancer (PCa). This study was designed to investigate the prognostic role of preoperative
methodsA total of 67 biopsy-confirmed localized PCa patients with mpMRI and
resultsPathological upgrading from mpMRI-TB to final RP specimens occurred in 38.8% (26/67) of the patients. Multivariable logistic regression analysis showed SUV
conclusion
Indexed as
Identifiers
33813594What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.